Leen Thielemans (PhD, Chief Development Officer) joined Dynacure in 2016 and established the basis of the overall development strategy for its lead program in CNM. Leen brings with her over fifteen years of experience in pharmaceutical R&D, from drug discovery to early clinical development. She previously worked at Johnson & Johnson, 4AZA-Elbion, Movetis, and Shire where she worked on a variety of projects in bringing compounds from target identification to clinical proof-of-concept, with a track record in translational strategy and personalized medicine, including biomarkers and patient-related outcomes. Leen Thielemans is a bio-engineer from the University of Leuven and an epidemiologist with a PhD in medical sciences. She also is managing partner and co-founder of 2Bridge.